338 related articles for article (PubMed ID: 11801545)
21. ZD-9331 AstraZeneca.
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2000 Sep; 1(1):141-9. PubMed ID: 11249590
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
23. Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.
Farrugia DC; Aherne GW; Brunton L; Clarke SJ; Jackman AL
Clin Cancer Res; 2000 Sep; 6(9):3646-56. PubMed ID: 10999757
[TBL] [Abstract][Full Text] [Related]
24. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
25. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
Popov I; Carrato A; Sobrero A; Vincent M; Kerr D; Labianca R; Raffaele Bianco A; El-Serafi M; Bedenne L; Paillot B; Mini E; Sanches E; Welch J; Collette L; Praet M; Wils J
Eur J Cancer; 2008 Oct; 44(15):2204-11. PubMed ID: 18707870
[TBL] [Abstract][Full Text] [Related]
26. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
27. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
28. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Stem Cells; 2000; 18(3):166-75. PubMed ID: 10840069
[TBL] [Abstract][Full Text] [Related]
29. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
[TBL] [Abstract][Full Text] [Related]
30. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival.
Tanaka-Nozaki M; Tajiri T; Tanaka N; Furukawa K; Takasaki H; Yoshimura K; Suzuki H; Naito Z; Sugizaki Y; Merk HF; Blömeke B; Kato S
Oncol Rep; 2003; 10(5):1425-9. PubMed ID: 12883718
[TBL] [Abstract][Full Text] [Related]
32. [Thymidylate synthase activity after preoperative administration of 5-FU in patients with gastric or colorectal cancer].
Arima S; Tachikawa D; Kawahara K; Futami K
Gan To Kagaku Ryoho; 2000 May; 27(5):703-10. PubMed ID: 10832438
[TBL] [Abstract][Full Text] [Related]
33. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
34. In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells.
Qin B; Tanaka R; Ariyama H; Shibata Y; Arita S; Kusaba H; Baba E; Harada M; Nakano S
Anticancer Drugs; 2006 Apr; 17(4):439-43. PubMed ID: 16550002
[TBL] [Abstract][Full Text] [Related]
35. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
Makower D; Wadler S
Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
[TBL] [Abstract][Full Text] [Related]
36. Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
Bendardaf R; Elzagheid A; Lamlum H; Algars A; Korkeila E; Ristamäki R; Collan Y; Syrjänen K; Pyrhönen S
Scand J Gastroenterol; 2007 Apr; 42(4):471-6. PubMed ID: 17454857
[TBL] [Abstract][Full Text] [Related]
37. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
Cunningham D; Zalcberg J; Smith I; Gore M; Pazdur R; Burris H; Meropol NJ; Kennealey G; Seymour L
Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
[TBL] [Abstract][Full Text] [Related]
39. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Jodrell DI; Bowman A; Rye R; Byrne B; Boddy A; Rafi I; Taylor GA; Johnston A; Clendeninn NJ
Br J Cancer; 1999 Feb; 79(5-6):915-20. PubMed ID: 10070890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
